BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Talero E, Alvarez de Sotomayor M, Sánchez-Fidalgo S, Motilva V. Vascular contribution of adrenomedullin to microcirculatory improvement in experimental colitis. Eur J Pharmacol 2011;670:601-7. [PMID: 21958875 DOI: 10.1016/j.ejphar.2011.09.032] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Romero M, Vera B, Galisteo M, Toral M, Gálvez J, Perez-vizcaino F, Duarte J. Protective vascular effects of quercitrin in acute TNBS-colitis in rats: the role of nitric oxide. Food Funct 2017;8:2702-11. [DOI: 10.1039/c7fo00755h] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Iesato Y, Yuda K, Chong KTY, Tan X, Murata T, Shindo T, Yanagi Y. Adrenomedullin: A potential therapeutic target for retinochoroidal disease. Progress in Retinal and Eye Research 2016;52:112-29. [DOI: 10.1016/j.preteyeres.2016.01.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
3 Kitamura K, Ashizuka S, Inatsu H, Kita T. Adrenomedullin as a Potential Therapeutic Agent for Refractory Ulcerative Colitis. In: Nakao K, Minato N, Uemoto S, editors. Innovative Medicine. Tokyo: Springer Japan; 2015. pp. 227-40. [DOI: 10.1007/978-4-431-55651-0_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
4 Kato J, Kitamura K. Bench-to-bedside pharmacology of adrenomedullin. Eur J Pharmacol 2015;764:140-8. [PMID: 26144371 DOI: 10.1016/j.ejphar.2015.06.061] [Cited by in Crossref: 51] [Cited by in F6Publishing: 42] [Article Influence: 7.3] [Reference Citation Analysis]
5 Rodríguez-Luna A, Ávila-Román J, González-Rodríguez ML, Cózar MJ, Rabasco AM, Motilva V, Talero E. Fucoxanthin-Containing Cream Prevents Epidermal Hyperplasia and UVB-Induced Skin Erythema in Mice. Mar Drugs 2018;16:E378. [PMID: 30308980 DOI: 10.3390/md16100378] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 7.5] [Reference Citation Analysis]
6 Ashizuka S, Inatsu H, Kita T, Kitamura K. Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series. Dig Dis Sci 2016;61:872-80. [PMID: 26470867 DOI: 10.1007/s10620-015-3917-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
7 Ashizuka S, Kita T, Inatsu H, Kitamura K. Adrenomedullin: A Novel Therapy for Intractable Ulcerative Colitis. Inflammatory Bowel Diseases 2013;19:E26-7. [DOI: 10.1002/ibd.22891] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
8 Martínez-Herrero S, Martínez A. Adrenomedullin regulates intestinal physiology and pathophysiology. Domest Anim Endocrinol 2016;56 Suppl:S66-83. [PMID: 27345325 DOI: 10.1016/j.domaniend.2016.02.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
9 Martínez-Herrero S, Larrayoz IM, Narro-Íñiguez J, Rubio-Mediavilla S, Martínez A. Lack of Adrenomedullin Aggravates Acute TNBS-Induced Colitis Symptoms in Mice, Especially in Females. Front Physiol 2017;8:1058. [PMID: 29311984 DOI: 10.3389/fphys.2017.01058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
10 Moura FA, de Andrade KQ, Dos Santos JCF, Araújo ORP, Goulart MOF. Antioxidant therapy for treatment of inflammatory bowel disease: Does it work? Redox Biol 2015;6:617-39. [PMID: 26520808 DOI: 10.1016/j.redox.2015.10.006] [Cited by in Crossref: 175] [Cited by in F6Publishing: 158] [Article Influence: 25.0] [Reference Citation Analysis]
11 Kita T, Kaji Y, Kitamura K. Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial. Drug Des Devel Ther 2020;14:1-11. [PMID: 32021087 DOI: 10.2147/DDDT.S225220] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
12 Geven C, Peters E, Schroedter M, Struck J, Bergmann A, McCook O, Radermacher P, Kox M, Pickkers P. Effects of the Humanized Anti-Adrenomedullin Antibody Adrecizumab (HAM8101) on Vascular Barrier Function and Survival in Rodent Models of Systemic Inflammation and Sepsis. Shock 2018;50:648-54. [PMID: 29324627 DOI: 10.1097/SHK.0000000000001102] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
13 Ashizuka S, Kuroishi N, Nakashima K, Inatsu H, Kita T, Kitamura K. Adrenomedullin: A Novel Therapy for Intractable Crohn's Disease with a Loss of Response to Infliximab. Intern Med 2019;58:1573-6. [PMID: 30713309 DOI: 10.2169/internalmedicine.1791-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
14 Kita T, Ashizuka S, Ohmiya N, Yamamoto T, Kanai T, Motoya S, Hirai F, Nakase H, Moriyama T, Nakamura M, Suzuki Y, Kanmura S, Kobayashi T, Ohi H, Nozaki R, Mitsuyama K, Yamamoto S, Inatsu H, Watanabe K, Hibi T, Kitamura K. Adrenomedullin for steroid-resistant ulcerative colitis: a randomized, double-blind, placebo-controlled phase-2a clinical trial. J Gastroenterol 2021;56:147-57. [PMID: 33140199 DOI: 10.1007/s00535-020-01741-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]